Liraglutide in the Prevention of Type 2 Diabetes After Gestational

Status Active, not recruiting

Clinical Trial Summary

Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12 months' liraglutide treatment could decrease the risk of T2D in obese women who have had gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group, once daily. Same laboratory tests are taken and instructions given at baseline 6 month and one year. After one year visits once a year until 5 years with same laboratory tests and measurements are taken.

Clinical Trial Description

Incidence of type 2 diabetes (T2D) is increasing along with pandemia of obesity. Gestational diabetes is the major risk factor for T2D in women and more than every tenth will develop gestational diabetes during pregnancy. T2D can be prevented by weight loss. Health care professionals should take advantage of this opportunity to prevent this devastating disease in women. Aim of the study is to investigate if 12 months' liraglutide treatment (1.8 mg) once daily could decrease the risk of T2D in obese women who have had gestational diabetes needing treatment with metformin and/or insulin. 100 women, who have had gestational diabetes with treatment with metformin and/or insulin and who have stopped lactation and are not pregnant are enrolled between 6 to 18 months after delivery. BMI should be ≥30 kg/m2. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group. Both treatments are given by similar device s.c. once daily during 365 days. Before starting the treatment, clinical examination and laboratory test are done. Similar dietary instructions are given. Same laboratory tests are taken and instructions given at 6 months and at one year after baseline. Additional follow-up call (AE reporting) is scheduled at 3 months and a drug dispensing visit at 9 months. After one year visits once a year until 5 years with same laboratory tests and measurements are taken. Primary end-point is development of T2D (fasting P-glucose >7 mmol/l and/ or 2 h >11 mmol/l in oral glucose tolerance test 75g, and/or HbA1c≥ 6.5 %) from year 1 to 5. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04324229
Study type	Interventional
Source	Turku University Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	February 7, 2020
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05081037` - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)	N/A
Active, not recruiting	`NCT03249896` - Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes	N/A
Terminated	`NCT03749889` - Low Carb vs Normal Carb in Pregnancy	N/A
Completed	`NCT03859193` - Education Nutritional Video for Gestational Diabetics	N/A
Recruiting	`NCT05037526` - Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care in Pregnancy Outcomes	N/A
Completed	`NCT06178250` - Placenta, Fetal Liver, Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester	N/A
Not yet recruiting	`NCT06310356` - Continuous Glucose Monitoring for Women With Gestational Diabetes	N/A
Not yet recruiting	`NCT06445530` - Nutrition Optimization and Community Upliftment for Postpartum Recovery	N/A
Recruiting	`NCT02590016` - Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial	Phase 4
Not yet recruiting	`NCT00883259` - Metformin and Gestational Diabetes in High-risk Patients: a RCTs	Phase 4
Withdrawn	`NCT01947699` - Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide	Phase 4
Recruiting	`NCT03008824` - Micronutrients in Pregnancy as a Risk Factor for Diabetes and Effects on Mother and Baby	N/A
Active, not recruiting	`NCT01340924` - Relationship Between Gestational Diabetes and Type 2 Diabetes
Completed	`NCT00534105` - Lipid Metabolism in Gestational Diabetes	N/A
Recruiting	`NCT00371306` - Comparison of Glucovance to Insulin for Diabetes During Pregnancy	N/A
Completed	`NCT03388723` - Intergenerational Programming of Diabesity in Offspring of Women With Gestational Diabetes Mellitus
Recruiting	`NCT04521712` - Postpartum Glycemia in Women at Risk For Persistent Hyperglycemia	N/A
Enrolling by invitation	`NCT03307486` - Gestational Diabetes: a Cohort Study	N/A
Active, not recruiting	`NCT03301792` - Group Versus Traditional Prenatal Care for Diabetes	N/A
Enrolling by invitation	`NCT05603793` - YoUng Adolescents' behaViour, musculoskeletAl heAlth, Growth & Nutrition

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes — Liragest

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms